Probi AB PBBIF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $17.00
- Day Range
- $19.20–19.20
- 52-Week Range
- $16.76–19.20
- Bid/Ask
- — / —
- Market Cap
- $218.77 Mil
- Volume/Avg
- 1,000 / 938
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.82
- Dividend Yield (Trailing)
- 0.66%
- Dividend Yield (Forward)
- 0.65%
- Total Yield
- 0.66%
Company Profile
Probi AB is engaged in probiotic research and development, manufacturing and sales of effective and well-documented probiotics. Its research relates to living microorganisms with scientific health benefits. The main fields of research are gut health, immune system and nutrient absorption, iron absorption, bone health and stress and recovery. It operates in Consumer Healthcare (CHC) and Functional Food (FF). The company operates in United States, Americas, excluding the United States , Sweden, EMEA, excluding Sweden, and APAC. The company's business is divided into three operating segments. These segments are based on a geographical division and consist of the regions Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia and the Pacific).
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 167
- Website
- https://www.probi.com
Comparables
Valuation
|
Metric
|
PBBIF
|
EKTA B
|
VITR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 17.40 | 33.84 |
Price/Book Value | 1.64 | 2.76 | 1.67 |
Price/Sales | 3.82 | 1.55 | 6.32 |
Price/Cash Flow | 34.81 | 10.28 | 24.62 |
Price/Earnings
PBBIF
EKTA B
VITR
Financial Strength
|
Metric
|
PBBIF
|
EKTA B
|
VITR
|
|---|---|---|---|
Quick Ratio | 6.00 | 0.82 | 2.30 |
Current Ratio | 8.07 | 1.09 | 3.06 |
Interest Coverage | −6.51 | 7.21 | 6.45 |
Quick Ratio
PBBIF
EKTA B
VITR
Profitability
|
Metric
|
PBBIF
|
EKTA B
|
VITR
|
|---|---|---|---|
Return on Assets (Normalized) | −0.04% | 4.76% | 1.99% |
Return on Equity (Normalized) | −0.04% | 14.30% | 2.43% |
Return on Invested Capital (Normalized) | −0.44% | 10.01% | 2.54% |
Return on Assets
PBBIF
EKTA B
VITR
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Nhdvvxrkqg | Cpwgh | $73.0 Bil | |
MKKGY
| Merck KGaA ADR | Tjvvzvngs | Hkydp | $70.8 Bil | |
HLN
| Haleon PLC ADR | Cpwslhz | Xknx | $38.2 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Cpcmclsm | Pbr | $14.6 Bil | |
VTRS
| Viatris Inc | Wmxndhmhp | Sslqj | $14.0 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Gsvfjyqmm | Rxw | $12.6 Bil | |
CTLT
| Catalent Inc | Psppgcmp | Zqlhm | $10.2 Bil | |
PRGO
| Perrigo Co PLC | Fbdvfpsk | Jgwby | $4.4 Bil | |
CURLF
| Curaleaf Holdings Inc | Byfglzm | Dsxzx | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Wsgngjsyt | Nwkkbnv | $3.6 Bil |